STYK1 Antibody

What is STYK1 and why is it important in cancer research?

STYK1 (Serine/Threonine/Tyrosine Kinase 1, also known as NOK) is a 48-50 kDa protein kinase that functions as a distant member of the FGFR/PDGFR family of tyrosine kinases. It has strong transforming capabilities and is significantly upregulated in various human malignancies, including colorectal, breast, lung, ovarian, prostate cancers, and acute leukemia .

STYK1 contains a tyrosine kinase domain (aa 118-372) and activates both MAPK and PI3K pathways, which are critical for cancer development and progression . Human STYK1 is 422 amino acids in length, containing a 25 aa N-terminus, a 21 aa putative transmembrane segment, and a 396 aa C-terminus . Despite having a putative transmembrane segment, STYK1 appears to be primarily intracellular, with specific staining localized to nuclei in some cell types .

Its importance stems from its role as a potential biomarker for tumor diagnosis and a predictor of poor prognosis in several cancer types .

What are the key considerations when selecting a STYK1 antibody for research?

When selecting a STYK1 antibody, researchers should consider:

• Antibody Type and Specificity: Choose between monoclonal (e.g., Clone #484713 ) for high specificity or polyclonal antibodies depending on your application. Validate specificity through Western blot to confirm detection of the expected 48 kDa band .

• Immunogen Details: Review the immunogen used (e.g., E. coli-derived recombinant human STYK1 Asp72-Val320 or specific regions like aa 50-200 ).

• Validated Applications: Confirm the antibody has been validated for your specific application:

• Species Reactivity: Most STYK1 antibodies detect human STYK1, but some also cross-react with mouse and rat samples. Human STYK1 shares 77% and 83% identity with mouse and canine STYK1, respectively, over aa 72-320 .

• Application-Specific Considerations: For immunohistochemistry, consider antigen retrieval methods (e.g., TE buffer pH 9.0 or citrate buffer pH 6.0 for certain antibodies ).

How can STYK1 expression be effectively detected in cancer cell lines?

STYK1 detection in cancer cell lines can be achieved through multiple complementary techniques:

Western Blot Analysis:

• Lyse cells using RIPA buffer (50 mM Tris-HCl [pH 8.0], 150 mM NaCl, 1% Nonidet P-40, 0.5% deoxycholate Na, 0.1% SDS) containing protease inhibitors

• Separate proteins by SDS-PAGE and transfer to PVDF membranes

• Probe with anti-STYK1 antibody (e.g., 2 μg/mL of MAB6668)

• Use appropriate HRP-conjugated secondary antibody

• STYK1 appears as a specific band at approximately 48 kDa

Immunofluorescence Analysis:

• Fix cells using paraformaldehyde and permeabilize with Triton X-100

• Incubate with STYK1 antibody (e.g., MAB6668 at 10 μg/mL for 3 hours at room temperature)

• Visualize using fluorophore-conjugated secondary antibodies

• STYK1 has been detected in the cytoplasm and nuclei of cancer cells

Flow Cytometry:

• Prepare single-cell suspensions

• Stain with STYK1 antibody followed by fluorophore-conjugated secondary antibody

• Include appropriate isotype controls (e.g., MAB003 when using MAB6668)

Cell lines validated for STYK1 detection include:

• Colorectal cancer: SW480, DLD clone 2C2

• Breast cancer: T47D

• Prostate cancer: PC-3

• Cervical cancer: HeLa

What protocols are recommended for STYK1 immunohistochemistry in tissue samples?

For optimal STYK1 immunohistochemistry in tissue samples:

Sample Preparation:

• Fix tissues in paraformaldehyde

• Perform ethanol gradient dehydration and xylene treatment

• Embed in paraffin and cut into 3 μm thick sections

• For tissue microarrays, follow standard construction protocols

Staining Protocol:

• Deparaffinization: Use standard xylene and ethanol gradient protocol

• Antigen Retrieval: Use TE buffer pH 9.0 or alternatively citrate buffer pH 6.0

• Blocking: Block endogenous peroxidase activity and non-specific binding

• Primary Antibody Incubation: Apply STYK1 antibody at appropriate dilution:

  • For rabbit polyclonal antibodies: 1:50-1:500

  • For specific antibodies like ab97451: 1:80

• Detection System: Use appropriate secondary antibody and detection reagents

• Counterstaining: Apply hematoxylin for nuclear visualization

• Mounting: Use permanent mounting media

Quantification Methods:

• Implement the histochemical score (h-score) for semiquantitative analysis

• Define high or low expression based on whether the h-score is higher or lower than the median

• Compare expression in tumor versus adjacent normal tissue

Validated Tissue Types:

• Colorectal cancer and adjacent normal tissues

• Prostate cancer tissues

• Mouse brain tissue

How can STYK1 knockdown experiments be optimized for cancer research?

STYK1 knockdown experiments require careful design and validation:

siRNA/shRNA Design:

• Validated target sequences for human STYK1 (NM_018423) include:

  • si1: 5′-GGTGGTACCTGAACTGTAT-3′

  • si2: 5′-CAGAGAATGGTCTTTCCCA-3′

  • si3: 5′-GGTGGAGGAGTCATTTCAT-3′

• For controls, use scrambled sequences (e.g., 5′-GCGCGCTTTGTAGGATTCG-3′)

Transfection Optimization:

• For transient knockdown, use lipid-based transfection reagents (e.g., FuGENE6)

• For stable knockdown, use lentiviral systems with appropriate selection markers

• Cell-specific optimization is required (e.g., PC9 cells for lung cancer, 22Rv1 or LNCaP for prostate cancer)

Validation Methods:

• mRNA level: Use RT-qPCR to confirm knockdown efficiency

• Protein level: Verify by Western blot

• Functional validation: Assess phenotypic changes

Experimental Readouts:

• Cell viability assays (e.g., using Cell Counting Kit-8)

• Colony formation assays (with crystal violet staining)

• Migration and invasion assays (consider real-time cell analysis systems for quantitative monitoring)

• Analysis of EMT biomarkers by Western blot

Example Results from Literature:
In NSCLC cells, STYK1 knockdown combined with EGFR TKI (afatinib) resulted in:

• 35% additional reduction in cell viability compared to single treatments

• Significantly reduced anchorage-independent growth in soft agar assays

• Counteracted afatinib-induced upregulation of FGF1

What are the best methods to investigate STYK1 protein interactions in cancer signaling pathways?

To investigate STYK1 protein interactions:

Co-immunoprecipitation:

• Transfect cells with tagged STYK1 constructs or use endogenous STYK1

• Lyse cells in non-denaturing buffer

• Immunoprecipitate with anti-STYK1 antibody or tag-specific antibody

• Analyze precipitated complexes by Western blot

• This approach has successfully identified interactions between STYK1 and EGFR variants

Proximity Ligation Assay:

• Useful for detecting in situ protein-protein interactions

• Requires primary antibodies from different species

• Can visualize subcellular localization of interactions

Cellular Co-localization:

• Perform immunofluorescence with antibodies against STYK1 and potential interacting proteins

• Use confocal microscopy for high-resolution imaging

• Quantify co-localization using appropriate software

Functional Validation:

• Co-expression of STYK1 with interacting partners

• Mutational analysis (e.g., kinase-dead K147R mutation)

• Inhibitor studies to disrupt specific interactions

Key STYK1 Interactions Identified:

• STYK1 selectively interacts with mutant EGFR with stronger affinity than wild-type EGFR

• This interaction is disrupted upon EGFR inhibition with afatinib or osimertinib

• EGFR-STYK1 interaction has been validated in NSCLC cells

What are common challenges in STYK1 antibody-based experiments and how can they be addressed?

Researchers frequently encounter these challenges when working with STYK1 antibodies:

Non-specific Binding:

• Problem: Multiple bands in Western blot or non-specific staining in IHC/IF

• Solution: Optimize antibody dilution (1:500-1:3000 for WB ), increase blocking stringency, include appropriate controls (isotype control antibody ), and validate with knockdown/knockout samples

Low Signal Intensity:

• Problem: Weak or absent STYK1 detection

• Solution: Optimize antigen retrieval (TE buffer pH 9.0 or citrate buffer pH 6.0 ), increase antibody concentration, extend incubation time, enhance detection system sensitivity

Variability Between Antibody Lots:

• Problem: Inconsistent results with different lots

• Solution: Perform lot-specific validation, maintain consistent antibody source, consider generating standard curves for each lot

Cell Type-Specific Considerations:

• Problem: Variable STYK1 detection across cell types

• Solution: Optimize protocols for each cell type, note that STYK1 expression varies significantly between cancer and normal tissues , and between different cancer types

Quantification Challenges:

• Problem: Difficulty in standardizing STYK1 expression levels

• Solution: Implement histochemical scoring (h-score) , use automated image analysis when possible, include reference standards

Validation Approach:
Confirm antibody specificity by:

• Testing on cells with known STYK1 expression (SW480, DLD-2C2, T47D, PC-3, HeLa )

• Comparing staining patterns with mRNA expression data

• Including STYK1 knockdown/knockout controls

• Testing across multiple applications (WB, IHC, IF)

How can researchers effectively validate the specificity of their STYK1 antibodies?

A systematic approach to validate STYK1 antibody specificity includes:

Positive and Negative Controls:

• Positive Controls: Use cell lines with confirmed STYK1 expression:

  • Colorectal: SW480, DLD clone 2C2

  • Breast: T47D

  • Prostate: PC-3

  • Cervical: HeLa

• Negative Controls: Include normal tissues with low STYK1 expression or cell lines with STYK1 knockdown

Multiple Detection Methods:

• Western Blot Validation:

  • Confirm single band at expected molecular weight (~48 kDa)

  • Include positive and negative control samples

  • Perform with reducing conditions and appropriate buffer systems (e.g., Immunoblot Buffer Group 1)

• Immunohistochemistry Validation:

  • Compare staining in cancer vs. normal tissues (e.g., 87.8% of CRC tissues are STYK1-positive vs. 48.4% of adjacent normal tissues)

  • Create paraffin-embedded blocks of cell lines with known STYK1 expression levels to serve as controls

  • Confirm staining pattern (typically cytoplasmic in cancer cells)

• Genetic Validation:

  • Correlate antibody staining with mRNA expression data

  • Test on cells with siRNA-mediated STYK1 knockdown

  • When possible, use STYK1 knockout models

Cross-Reactivity Assessment:

• Test on samples from multiple species to confirm expected cross-reactivity

• Human STYK1 shares 77% identity with mouse and 83% with canine STYK1 over aa 72-320

Protocol Optimization:

• Determine optimal antibody concentration for each application

• Test multiple antigen retrieval methods for IHC

• Validate across different sample preparation methods

How is STYK1 being investigated as a biomarker and therapeutic target in cancer research?

STYK1 is emerging as a significant cancer biomarker and potential therapeutic target:

Prognostic Biomarker Applications:

• Colorectal Cancer: Increased STYK1 expression correlates with disease progression, metastasis, and poor prognosis

• Non-Small Cell Lung Cancer: STYK1 overexpression correlates with poor prognosis and advanced stage

• Acute Leukemia: STYK1 has been identified as a novel drug resistance factor and potential predictor of therapeutic response

Diagnostic Applications:

• STYK1 mRNA expression has been proposed as a tool to support the diagnosis of breast, lung, and colorectal carcinomas

• In colorectal cancer studies, 87.8% (310/353) of cancerous tissues showed STYK1-positive staining compared to 48.4% (171/353) of adjacent normal tissues

Therapeutic Target Potential:

• EGFR-Mutant Cancers: Co-targeting STYK1 and EGFR shows enhanced anti-cancer effects:

  • Combined targeting resulted in an additional 35% reduction in cell viability in NSCLC cells

  • STYK1 knockdown counteracted afatinib-induced upregulation of FGF1, potentially reducing drug tolerance mechanisms

• Prostate Cancer: STYK1 knockdown drastically attenuated growth of prostate cancer cells, suggesting potential as a therapeutic target for castration-resistant prostate cancer

Molecular Mechanisms Under Investigation:

• STYK1 activation of MAPK and PI3K pathways

• Role in epithelial-mesenchymal transition (EMT)

• Interaction with mutant EGFR and regulatory mechanisms

• Regulation of FGF1 expression as a potential resistance mechanism to targeted therapies

What are the most promising experimental approaches to study STYK1's role in drug resistance mechanisms?

To investigate STYK1's role in drug resistance, researchers are employing these approaches:

Combination Therapy Models:

• Co-targeting STYK1 with established therapies:

  • EGFR TKIs (afatinib, osimertinib) in NSCLC

  • Potential applications in other cancer types with targeted therapies

Drug-Tolerant Cell Models:

• Generate drug-tolerant cell lines (e.g., gefitinib-tolerant PC9 cells)

• Analyze STYK1 expression in these models (STYK1 is overexpressed in gefitinib- and WZ4002-tolerant PC9 cells)

• Compare drug-sensitive and drug-resistant isogenic cell pairs

Transcriptomic and Proteomic Analyses:

• RNA sequencing to identify STYK1-regulated genes during drug treatment

• Example finding: STYK1 knockdown counteracts the afatinib-induced upregulation of FGF1 in PC9 cells

• Proteomic analysis to identify interaction partners and pathway components

Functional Assays:

• Soft agar colony formation assays to assess anchorage-independent growth

• STYK1 overexpression diminishes the effect of afatinib on colony growth

• Cell viability and apoptosis assays with combination treatments

Mechanistic Investigations:

• Co-immunoprecipitation studies to identify interactions with drug targets

• STYK1 selectively interacts with mutant EGFR; this interaction is disrupted by EGFR inhibition

• Signaling pathway analysis focusing on MAPK and PI3K pathways

In Vivo Models:

• Xenograft models with STYK1 knockdown/overexpression

• Patient-derived xenografts to validate clinical relevance

• Treatment with targeted therapies alone or in combination with STYK1 inhibition

Example Research Finding:
STYK1-EGFR-FGF1 axis in drug tolerance to EGFR TKIs:

• EGFR inhibition leads to upregulation of FGF1

• STYK1 regulates FGF1 expression

• STYK1 knockdown prevents FGF1 upregulation upon EGFR inhibition

• This mechanism may reduce the pool of drug-tolerant cells from which resistance emerges

How does STYK1 expression in immune cells impact cancer biology and immunotherapy response?

Recent research has revealed STYK1 expression in specific immune cell populations:

STYK1 in NK1.1+ Lymphocytes:

• STYK1 is specifically expressed in lymphocytes positive for Killer cell lectin-like receptor subfamily B, member 1 (NK1.1)

• Expression observed in:

  • Natural Killer (NK) cells

  • αβ invariant NKT (iNKT) cells

  • γδ NKT cell lineages

• STYK1 expression is present in thymic, but not in peripheral invariant αβ iNKT cells

Functional Significance:

• Despite specific expression pattern, STYK1 appears dispensable for development and function of these lineages based on knockout studies

• This raises questions about potential compensatory mechanisms or context-dependent functions

Research Implications for Cancer Immunology:

• STYK1's role in NK cells could potentially influence anti-tumor immune responses

• The significance of STYK1 upregulation in both cancer cells and specific immune cells remains to be fully elucidated

• Possible implications for immunotherapy responses, particularly in cancers where STYK1 is highly expressed

Methodological Approaches:

• Use of Styk1 reporter mouse models to track expression in immune populations

• Flow cytometry for immune cell subset analysis

• Single-cell RNA sequencing to identify STYK1-expressing immune populations in the tumor microenvironment

• Co-culture systems to study cancer-immune cell interactions with STYK1 manipulation

What is the significance of STYK1's subcellular localization in relation to its oncogenic function?

STYK1's subcellular localization presents intriguing research questions:

Observed Localization Patterns:

• Primarily cytoplasmic localization in colorectal cancer cells

• Nuclear localization observed in PC-3 prostate cancer cells

• Contains a putative transmembrane segment but appears to function intracellularly

Methodological Approaches to Study Localization:

• Subcellular Fractionation: Separate nuclear, cytoplasmic, and membrane fractions followed by Western blot analysis

• Immunofluorescence Microscopy: Co-staining with organelle markers to determine precise localization

• Live-Cell Imaging: Using fluorescently tagged STYK1 to monitor dynamic localization

• Mutational Analysis: Study localization patterns of STYK1 with mutations in potential localization signals

Research Questions to Address:

• Does STYK1 localization change during cancer progression?

• How does the putative transmembrane segment influence localization and function?

• Does subcellular localization determine interaction partners and signaling outcomes?

• Can targeting specific localization patterns provide therapeutic opportunities?

Relation to Function:

• Nuclear localization may suggest potential roles in transcriptional regulation

• Cytoplasmic localization aligns with known signaling activities through MAPK and PI3K pathways

• The apparent discrepancy between structural predictions (transmembrane domain) and observed localization requires further investigation